Despite their benefits to patients, innovative treatments, including biologics, come at a high cost to the healthcare system, and those in a position to make coverage decisions for these products must grapple with these therapies’ affordability. During the ISPOR 2019 meeting, researchers presented findings on how health plan restrictions could limit orphan drug coverage—and encourage biosimilar use—as a means to manage their budgets.
Despite their benefits to patients, innovative treatments, including biologics, come at a high cost to the healthcare system, and those in a position to make coverage decisions for these products must grapple with these therapies’ affordability. During the ISPOR 2019 meeting, researchers presented findings on how health plan restrictions could limit orphan drug coverage—and encourage biosimilar use—as a means to manage their budgets.
First, a research group presented findings from their investigation of whether US commercial health plan restrictions are likely to be implemented as a means to control spending on orphan drugs.1
Using the Tufts Medical Center Specialty Drug and Evidence Coverage database, which includes information on coverage decisions among 17 of the 20 largest US commercial plans, the team estimated a drug’s budget impact by considering its annual cost and the US prevalence of the disease for which it is indicated.
They considered patient subgroup restrictions, step therapy, limitations on which specialists can prescribe a drug, or any other restriction type, and included 2168 coverage decisions in their analysis.
They found that the odds of restricted coverage were 1.5 greater for orphan drugs with the largest budget impacts versus those with the smallest budget impacts, and that noncancer treatment, availability of alternative therapies, number of years since FDA approval, and self-administration of a drug were all associated with increased likelihood of restriction.
Another research team presented results of a survey of health plan executives that sought to investigate how health plans will address biosimilars as an alternative to higher-cost innovator drugs.2
The investigators conducted an online survey of 85 health plan executives on their plan information, including expected biosimilar coverage, restrictions, and copays. Plans represented by the respondents were national, regional, and local, and covered commercial, Medicaid, Medicare, employer- or self-funded, and integrated delivery network members.
In total, 46% of respondents reported their plan’s pharmacy benefit manager (PBM) as their specialty pharmacy provider, and 58% reported that providers were restricted with respect to products. Biosimilar use was expected to be allowed for all reference product indications by 58.8% of respondents, and 31.5% reported that their plans will restrict biosimilar use to approved indications. Another 9.8% said that indications will be used as the basis for copays for biosimilars, and 10% said that biosimilars are expected to be the only product made available.
Fifty-eight percent expected copays to be discounted off the innovator product’s copay, and 32% expected copays to vary based on the timing of a given biosimilar’s approval.
Respondents said they would provide education about biosimilars through different copays for biosimilars versus reference products (64.7%), prescriber and patient mailings (76.5%), prescriber and patient phone calls (51%).
In total, 66% of respondents said that they expect 20% savings from biosimilars within 5 years, the researchers found.
References
1. Margaretos N, Neumann PJ, Kim DD, Chambers J. Are health plans more likely to restrict coverage of orphan drugs with larget budget impacts? Presented at: International Society for Pharmacoeconomics and Outcomes Research 24th Annual International Meeting; May 18-22, 2019; New Orleans, Louisiana. Abstract PRO42.
2. Brook R, Smeeding JE, Carlise JA, Sax MJ. Management of specialty drugs, specialty pharmacies, and biosimilars in the United States. Presented at: International Society for Pharmacoeconomics and Outcomes Research 24th Annual International Meeting; May 18-22, 2019; New Orleans, Louisiana. Abstract PNS112.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.